Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology III1 Apr 2018MP88-16 THE DOWNREGULATION AND TUMOR SUPPRESSIVE FUNCTION OF RASAL2 IN RENAL CELL CARCINOMA Ke Hui, Kaijie Wu, Jer-Tsong Hsieh, and Dalin He Ke HuiKe Hui More articles by this author , Kaijie WuKaijie Wu More articles by this author , Jer-Tsong HsiehJer-Tsong Hsieh More articles by this author , and Dalin HeDalin He More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2936AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Patients with renal cell carcinoma (RCC) often develop resistance to anti-vascular drug and eventually succumb to disease. However, the underlying molecular mechanism of drug resistance remains poorly understood. In this study, we demonstrated that RASAL2, a RAS GTPase activating protein (RASGAP), played suppressive role in in RCC by targeting tumor angiogenesis. METHODS RCC and its paired normal kidney tissues were immunohistochemically stained for RASAL2 expression. Databases downloaded from TCGA or GEO were used to analyze the methylation status of RASAL2 and the correlation between RASAL2 and c-FOS or VEGFA in RCC tissues. In vitro, RASAL2 gain-function in 786-O cells or loss-function in ACHN cells were measured for the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay, ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tunorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in RCC tissues and xenografts were detect by immunohistochemical (IHC) staining. RESULTS The expression of RASAL2 was downregulated in RCC tissues, and RASAL2 mRNA was inversely correlated with RASAL2 methylation or c-FOS mRNA or VEGFA mRNA in RCC tissues. Overexpression of RASAL2 in 786-O cells could inhibit the recruitment and tube formation of HUVECs, while RASAL2 knockdown (KD) in ACHN cells enhanced the recruitment and tube formation of HUVECs in vitro. Also, overexpression of RASAL2 could inhibit tumorigenecity of xenografts. Mechanistically, RASAL2 KD could enhance the phosphorylation of GSK3 and upregulate the expression of c-FOS and VEGFA. Furthermore, RASAL2 was inversely correlated with VEGFA and CD31 in tissues from human RCC specimens and xenografts. CONCLUSIONS RASAL2 was downregulated in RCC tissues, which could lead to tumor angiogenesis via p-GSK3/c-FOS/VEGFA signaling pathway. Therefore, RASAL2 could be a potential target to prevent patients with RCC from resistance to anti-vascular therapy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1203-e1204 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ke Hui More articles by this author Kaijie Wu More articles by this author Jer-Tsong Hsieh More articles by this author Dalin He More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Knockdown of ALPK2 Blocks Development and Progression of Renal Cell Carcinoma

The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A

Correction: Acylglycerol Kinase Promotes Tumour Growth and Metastasis Via Activating the PI3K/AKT/GSK3β Signalling Pathway in Renal Cell Carcinoma

KLF2-induced circZKSCAN1 potentiates the tumorigenic properties of clear cell renal cell carcinoma by targeting the miR-1294/PIM1 axis

Low Expression of PDK1 Inhibits Renal Cell Carcinoma Cell Proliferation, Migration, Invasion and Epithelial Mesenchymal Transition Through Inhibition of the PI3K-PDK1-Akt Pathway.

KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation

Role of APLP2 in the Prognosis and Clinicopathology of Renal Cell Carcinoma.

STK39 Blockage by RNA Interference Inhibits the Proliferation and Induces the Apoptosis of Renal Cell Carcinoma

The Downregulation of Choline Kinase Alpha Inhibits Clear Cell Renal Cell Carcinoma Proliferation and Metastasis Via the MAPK and PI 3 K / AKT Pathways

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

Decreased PANK1 expression in kidney renal clear cell carcinoma: impact on cell apoptosis, invasion, migration, and epithelial-mesenchymal transition

Knockdown Of Pkm2 Suppresses Tumor Growth And Invasion In Lung Adenocarcinoma

Mp88-16 the downregulation and tumor suppressive function of rasal2 in renal cell carcinoma

PDZK1 Inhibits the Development and Progression of Renal Cell Carcinoma by Suppression of SHP-1 Phosphorylation

PAK1 Expression Determines Poor Prognosis and Immune Evasion in Metastatic Renal Cell Carcinoma Patients.

Integrated analysis identifies microRNA‐188‐5p as a suppressor of AKT/mTOR pathway in renal cancer

Knockdown of PIK3R6 impedes the onset and advancement of clear cell renal cell carcinoma

Alpha Protein Kinase 2 Promotes Esophageal Cancer Via Integrin Alpha 11

ALK-Rearranged Renal Cell Carcinoma (ALK-RCC): a Study of Three Cases with Clinicopathologic Features and Effect of Postoperative Adjuvant Immunotherapy

ALKBH1 contributes to renal cell carcinoma progression by reducing N6-methyladenine of GPR137